Acute and Chronic Respiratory Symptoms among Primary Care Patients Who Smoke Crack Cocaine

被引:0
作者
Pamela Leece
Nikhil Rajaram
Susan Woolhouse
Margaret Millson
机构
[1] University of Toronto,Public Health and Preventive Medicine Residency Program
[2] University of Western Ontario,Department of Family Medicine
[3] University of Toronto,Dalla Lana School of Public Health
来源
Journal of Urban Health | 2013年 / 90卷
关键词
Addictions; Crack cocaine; Asthma; COPD; Primary care;
D O I
暂无
中图分类号
学科分类号
摘要
Among inner-city populations in Canada, the use of crack cocaine by inhalation is prevalent. Crack smoking is associated with acute respiratory symptoms and complications, but less is known about chronic respiratory problems related to crack smoking. There is also a gap in the literature addressing the management of respiratory disease in primary health care among people who smoke crack. The purpose of our study was to assess the prevalence of acute and chronic respiratory symptoms among patients who smoke crack and access primary care. We conducted a pilot study among 20 patients who currently smoke crack (used within the past 30 days) and who access the “drop-in clinic” at an inner-city primary health care center. Participants completed a 20- to 30-min interviewer-administered survey and provided consent for a chart review. We collected information on respiratory-related symptoms, diagnoses, tests, medications, and specialist visits. Data were analyzed using frequency tabulations in SPSS (version 19.0). In the survey, 95 % (19/20) of the participants reported having at least one respiratory symptom in the past week. Thirteen (13/19, 68.4 %) reported these symptoms as bothersome. Chart review indicated that 12/20 (60 %) had a diagnosis of either asthma or chronic obstructive pulmonary disease (COPD), and four participants (4/20, 20 %) had a diagnosis of both asthma and COPD. Majority of the participants had been prescribed an inhaled medication (survey 16/20, 80 %; chart 12/20, 60 %). We found that 100 % (20/20) of the participants currently smoked tobacco, and 16/20 (80 %) had smoked both tobacco and marijuana prior to smoking crack. Our study suggests that respiratory symptoms and diagnoses of asthma and COPD are prevalent among a group of patients attending an inner-city clinic in Toronto and who also smoke crack. The high prevalence of smoking tobacco and marijuana among our participants is a major confounder for attributing respiratory symptoms to crack smoking alone. This novel pilot study can inform future research evaluating the primary health care management of respiratory disease among crack smokers, with the aim of improving health and health care delivery.
引用
收藏
页码:542 / 551
页数:9
相关论文
共 56 条
[1]  
Fischer B(2005)Illicit opioid use in Canada: comparing social, health and drug use characteristics of untreated users in five cities (OPICAN study) J Urban Health 82 250-266
[2]  
Rehm J(2001)Airway effects of marijuana, cocaine, and other inhaled illicit agents Curr Opin Pulm Med 7 43-61
[3]  
Brissette S(1995)The pulmonary complications of crack cocaine. A comprehensive review Chest 107 233-240
[4]  
Tashkin DP(2006)Crack across Canada: comparing crack users and crack non-users in a Canadian multi-city cohort of illicit opioid users Addiction 101 1760-1770
[5]  
Haim DY(2007)Crack use in North American cities: the neglected ‘epidemic’ Addiction 102 1340-1341
[6]  
Lippmann ML(2003)Meeting the health care needs of female crack users Women Health 37 1-17
[7]  
Goldberg SK(2004)The prevalence of psychiatric disorder among a community sample of crack cocaine users: an exploratory study with practical implications J Nerv Ment Dis 192 503-507
[8]  
Walkenstein MD(2002)Sexual risk behaviours and STIs in drug abuse treatment populations whose drug of choice is crack cocaine Int J STD AIDS 13 769-774
[9]  
Fischer B(2011)Access to primary health care among homeless adults in Toronto, Canada: results from the Street Health survey Open Med 5 e94-e103
[10]  
Rehm J(2008)Documenting practices and perceptions of ‘safer’ crack use: a Canadian pilot study Int J Drug Policy 19 339-341